1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Swedencare AB (publ)

Swedencare AB (publ)

SWDCF
Swedencare AB (publ)US flagOther OTC
2.82
USD
+0.01
- -
451.07MMarket Cap
Swedencare AB (publ)
SWDCF
(Other OTC)

Recent

price

2.82

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.31
0.5
0.77
1.08
1.26
1.61
2.76
6.88
11.87
14.73
15.93
16.81
16.36
Revenue per Share
0.05
0.12
0.14
0.22
0.3
0.38
0.38
0.49
0.61
0.37
0.62
0.35
0.41
Basic EPS, GAAP
0.06
0.05
0.03
0.15
0.16
0.36
0.41
0.88
1.19
2.57
1.81
1.73
1.83
Free Cash Flow per Basic Share
- -
0.03
- -
- -
- -
- -
0.13
0.15
0.2
0.22
0.23
0.25
0.25
Dividend per Share
- -
0.24
0.81
0.88
0.01
1.05
1.2
1.27
1.32
1.44
1.83
1.92
0.01
Book Value per Share
0.07
0.22
0.09
0.3
0.61
1
2.43
-3.1
-5.85
-4.42
-2.96
-6.09
-6.81
Tangible Book Value per Share
77
55
70
79
79
79
87
112
155
159
159
160
159
Basic Weighted Avg Shares
24
27
54
85
99
127
240
770
1,843
2,338
2,530
2,683
2,603
Sales/Revenue/Turnover
18.85
31.8
21.65
25.61
28.85
29.04
17.12
8.39
6.52
7.63
8.77
5.09
6.76
Operating Margin (%)
- -
- -
2
1
1
3
13
73
269
310
316
311
310
Depreciation Expense
4
7
10
17
23
30
33
55
94
59
99
56
65
Net Income, GAAP
23.56
22.58
17.63
20.5
19.83
18.47
16.03
4.01
- -
27.74
34.29
32.73
41.24
Effective Tax Rate (%)
14.55
24.59
18.06
19.9
23.46
23.6
13.9
7.09
5.13
2.51
3.91
2.07
2.49
Profit Margin (%)
9
11
21
30
38
64
335
337
697
694
774
685
772
Working Capital
- -
- -
17
9
2
2
139
704
1,867
1,626
1,427
1,756
1,774
LT Debt
5
13
57
74
98
131
918
2,420
7,461
7,207
8,032
6,665
6,923
Total Equity
- -
62.46
19.35
19.38
22.14
23.8
5.52
2.9
- -
1.4
1.57
1
1.13
Return on Invested Capital (%)
- -
101.84
21.01
20.73
48.26
61.55
18.86
11.04
- -
6.3
8.37
4.89
6.32
Return on Capital (%)
- -
101.65
28.01
27.07
66.81
71.55
35.74
44.5
54.54
27.04
38.07
18.58
4,050
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
43
40
40
LT Borrowings
1,247
1,703
1,774
LT Finance Leases
180
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
159
159
160
Market Capitalization
7,586
6,404
6,201

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,170
1,458
1,161
Cash, Cash Equivalents & STI
187
527
124
Accounts Receivable, Net
293
291
294
Inventories
476
465
562
Total Current Liabilities
396
397
389
Payables & Accruals
- -
- -
- -
ST Debt
43
40
40
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
138.96%
72.57%
-17.02%
Free Cash Flow
100.28%
70.28%
-4.24%
Net Income, GAAP
32.08%
24.73%
-43.88%
Sales/Revenue/Turnover
69.17%
80.29%
6.04%
Total Cash Common Dividend
- -
32.86%
9.59%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
599
632
644
665
2,530
2025
646
649
685
- -
2,683
2026
655
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.13
0.15
0.15
0.62
2025
0.15
-0.04
0.1
- -
0.35
2026
0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.23
- -
- -
0.23
2025
- -
0.25
- -
- -
0.25
2026
- -
- -
- -
- -
- -
Similar Companies
Hikal Limited (HIKAL.NS)
TerrAscend Corp. (TSND.TO)
Allied Corp. (ALID)
Siegfried Holding AG (SGFEF)
Mercanto Holdings Inc. (MUSH.V)
Aida Pharmaceuticals, Inc. (AIDA)
Business
Swedencare AB (publ) develops, manufactures, markets and sells premium healthcare products for pets including cats, dogs and horses. The company offers an extensive portfolio across nutraceuticals, dental care, topicals/dermatology, treats and pharmaceuticals through brands such as ProDen PlaqueOff, NaturVet, nutravet, Innovet, Pet MD, NutriScience, Animal Pharmaceuticals, Healthy Breeds, Riley's, Rx Vitamins, Stratford, VETCLASSICS and VetWELL; ProDen PlaqueOff features the unique organic seaweed-based A.N ProDen ingredient for oral health in powder, dental bites and cat variants, while NaturVet and VETCLASSICS provide veterinarian-formulated supplements in tablets, soft chews, powders and liquids for wellness, training and yard care, and Innovet targets orthopedics, dermatology and other therapeutic areas with science-based formulations. Founded in 1993 and headquartered in Malmö, Sweden, Swedencare operates globally in approximately 65 countries through subsidiaries in nine nations, a distribution network reaching veterinarians, pet stores, pharmacies, animal hospitals and online channels, with primary segments in North America, Europe and production. Recent strategic moves include the 2025 acquisition of Summit Veterinary Pharmaceuticals Limited for GBP 30 million to strengthen presence in the UK Animal Health Specials market, completion of the Pack Approved asset acquisition, and 2024 purchases of MedVant Inc., Riley's Organics, Vet Worthy and Healthy Solutions for Pets to expand in Canada and bolster online veterinary sales. The company listed on the OTCQX Market in 2024 to enhance North American share accessibility and continues leveraging synergies for innovative pet solutions.

Company News

APIChat

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Q4 2025 Earnings Call Transcript